Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> d his

     (FILE 'HOME' ENTERED AT 06:13:43 ON 10 OCT 2002)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 06:13:50 ON 10 OCT 2002
L1             3 S 112111-47-4 OR 112111-43-0 OR 68693-11-8

     FILE 'HCAPLUS' ENTERED AT 06:14:48 ON 10 OCT 2002
L2           144 S L1
L3             3 S L1 (L) PRP/RL
                 E SOLUBILITY/CT
                 E E3+ALL
L4         19368 S E3,E4,E2+NT
L5         13918 S E24+NT
L6         37949 S E26+NT OR E27+NT OR E29+NT OR E32+NT
L7             1 S L2 AND L4-L6
L8           157 S MODAFINIL OR PROVIGIL OR MODIODAL OR CEP1538 OR CEP 1538 OR C
L9             0 S 2 BENZHYDRYLSULFINYL ACETAMIDE
L10            2 S  BENZHYDRYLSULFINYL ACETAMIDE
L11            0 S  BENZHYDRYL SULFINYL ACETAMIDE
L12            0 S  BENZHYDRYL SULFINYLACETAMIDE
L13            6 S  BENZHYDRYLSULFINYLACETAMIDE
L14            2 S DIPHENYLMETHYL SULFINYL ACETAMIDE
L15            0 S DIPHENYLMETHYL SULPHINYL ACETAMIDE
L16            0 S DIPHENYLMETHYLSULFINYL ACETAMIDE
L17            0 S DIPHENYLMETHYLSULFINYLACETAMIDE
L18            0 S DIPHENYL METHYLSULFINYL ACETAMIDE
L19            0 S DIPHENYL METHYL SULFINYL ACETAMIDE
L20            0 S DIPHENYL METHYL SULFINYLACETAMIDE
L21            0 S DIPHENYL METHYLSULFINYLACETAMIDE
L22            1 S L4-L6 AND L8,L10,L13,L14
L23            3 S L3,L7,L22
                 E BIOLOGICAL TRANSPORT/CT
                 E E3+ALL
L24       261937 S E4+NT
L25            7 S L2,L8 AND L24
L26            9 S L23,L25
L27            9 S L26 AND L2-L26

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 06:20:58 ON 10 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Oct 2002  VOL 137 ISS 15
FILE LAST UPDATED: 9 Oct 2002  (20021009/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
```

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d l27 bib abs hitstr tot

L27 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:354556 HCAPLUS
DN 137:98838
TI Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
AU Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.
CS Departments of Medicinal Chemistry, Cheminformatics, Computational Analytical and Structural Sciences, and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA, 19406-0939, USA
SO Journal of Medicinal Chemistry (2002), 45(12), 2615-2623
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property. Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt. That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability. The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set. Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area .ltoreq.140 .ANG.2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat. Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd. Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate. A threshold permeation rate is a prerequisite of oral bioavailability. The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.
IT **68693-11-8, Modafinil**
RL: PKT (Pharmacokinetics); **PRP (Properties)**; THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. properties effect on oral bioavailability of drug candidates)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:107306 HCAPLUS

DN 136:167176
TI Oxidative process for the preparation of crystalline and pure **modafinil** and process for producing new **modafinil** crystal morphologs
IN Singer, Claude; Gershon, Neomi; Ceausu, Arina; Lieberman, Anita; Aronhime, Judith
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010125	A1	20020207	WO 2001-US23689	20010727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002043207	A1	20020418	US 2001-916885	20010727
PRAI	US 2000-221110P	P	20000727		
	US 2000-226491P	P	20000818		
	US 2000-229160P	P	20000830		
	US 2000-230088P	P	20000905		
	US 2001-259332P	P	20010102		

AB High-purity **modafinil** is prepd. by: (a) oxidizing 2-[(diphenylmethyl)thio]acetamide with aq. H2O2 in a mixt. of a mineral acid with an alc. or phase transfer catalyst; (b) pptg. a solid-contg. **modafinil** from the mixt.; and (c) sepg. the mixt. from the pptd. solid **modafinil** free of sulfone byproducts of over-oxidn. and other byproducts. New cryst. Forms II-VI of **modafinil** and processes for prepg. them using heating and crystn are presented; X-ray powder diffractograms of the new crystal **modafinil** forms are presented.
IT **68693-11-8P, Modafinil**
RL: PEP (Physical, engineering or chemical process); **PRP (Properties)**; PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(oxidative process for the prepn. of cryst. and pure **modafinil** and process for producing new **modafinil** crystal morphologs)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:104621 HCAPLUS
DN 136:145265
TI A pharmaceutical composition for the treatment of attention deficit

hyperactivity disorder (ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent
IN Watsky, Eric Jacob; Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1177798	A2	20020206	EP 2001-306455	20010727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002016334	A1	20020207	US 2001-865793	20010525
BR 2001003169	A	20020528	BR 2001-3169	20010731
PRAI US 2000-221718P	P	20000731		

AB Pharmaceutical compns. are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.
IT **68693-11-8, Modafinil**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotine receptor partial agonist and anti-attention deficit hyperactivity disorder agent for pharmaceutical compn. for treatment of attention deficit hyperactivity disorder)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:560443 HCAPLUS
DN 135:338915
TI Optimization of a mathematical topological pattern for the prediction of antihistaminic activity
AU Duart, M. J.; Garcia-Domenech, R.; Anton-Fos, G. M.; Galvez, J.
CS Departamento Ciencias Quimicas, Universidad Cardenal Herrera-CEU, Spain
SO Journal of Computer-Aided Molecular Design (2001), 15(6), 561-572
CODEN: JCADEQ; ISSN: 0920-654X
PB Kluwer Academic Publishers
DT Journal
LA English
AB Mol. topol. was used to develop a math. model capable of classifying compds. according to antihistaminic activity. The equations used for this purpose were derived using multi-linear regression and linear discriminant anal. The topol. pattern of activity obtained allows the reliable prediction of antihistaminic activity in drugs frequently used for other therapeutic purposes. Based on the results, the proposed pattern is seemingly only valid for drugs that interact with histamine through competitive inhibition with H1 receptors.
IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **PRP (Properties)**; THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(optimization of a math. topol. pattern for the prediction of antihistaminic activity)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:182256 HCAPLUS
DN 135:28931
TI **Modafinil** does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs
AU Ferraro, L.; Tanganelli, S.; Fuxe, K.; Bebe, B. W.; Tomasini, M. C.; Rambert, F. A.; Antonelli, T.
CS Section of Pharmacology, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, 44100, Italy
SO Brain Research (2001), 894(2), 307-310
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
AB **Modafinil** did not affect spontaneous and K+-evoked [3H]5-HT efflux from cortical synaptosomes while it increased K+-evoked tritium efflux from cortical slices, an action that became stronger in the presence of paroxetine. In contrast, DL-fenfluramine and fluoxetine were able to enhance spontaneous and/or K+-evoked tritium efflux from synaptosomes and slices. These results suggest that **modafinil** does not affect 5-HT transmission from cortical synaptosomes and that its 5-HT releasing action is different from that of DL-fenfluramine and fluoxetine.
IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**modafinil** does not affect serotonin efflux from rat frontal cortex synaptosomes)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:481971 HCAPLUS
DN 134:80725
TI Antiparkinsonian and neuroprotective effects of **modafinil** in the MPTP-treated common marmoset
AU Jenner, P.; Zeng, B.-Y.; Smith, L. A.; Pearce, R. K. B.; Tel, B.; Chancharme, L.; Moachon, G.
CS King's and St Thomas' School of Biomedical Sciences, Guy's, Division of

Pharmacology and Therapeutics, Neurodegenerative Disease Research Centre, King's College, London, SE1 1UL, UK
SO Experimental Brain Research (2000), 133(2), 178-188
CODEN: EXBRAP; ISSN: 0014-4819
PB Springer-Verlag
DT Journal
LA English
AB The psychostimulant drug, **modafinil**, protects rodents against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, striatal ischemia and partial transection of the nigro-striatal pathway. We now report on the ability of **modafinil** to reverse motor disability in MPTP-treated common marmosets and to prevent MPTP-induced nigral cell death in this species. In the initial expts., adult common marmosets were treated with MPTP to produce stable motor deficits. The subsequent administration of **modafinil** (10, 30 or 100 mg/kg/day, p.o.) produced a dose-dependent reversal of motor disability. In a subsequent expt., normal common marmosets were concurrently treated with 10, 30 or 100 mg/kg of **modafinil** once daily by gavage during acute MPTP administration (daily for 5 days), continuing for 2 wk after the last dose of MPTP. **Modafinil** dose-dependently prevented the decline in motor activity normally produced by MPTP treatment. MPTP treatment caused a 76% loss of nigral tyrosine-hydroxylase-immunoreactive cells in placebo-treated animals, and this was dose-dependently prevented by **modafinil**. At the highest dose (100 mg/kg/day) of **modafinil**, there was no significant loss of tyrosine-hydroxylase-immunoreactive cells in the substantia nigra compared with normal animals. MPTP treatment also reduced striatal dopamine uptake sites by 95%, as measured by specific [3H]-mazindol binding, compared with normal controls. **Modafinil** treatment dose-dependently reduced the loss of specific [3H]-mazindol binding. Behavioral and morphol. evidence in the present study indicate a potential antiparkinsonian and neuroprotective role for **modafinil**, which may form a new pharmacol. approach to the treatment of Parkinson's disease.
IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiparkinsonian and neuroprotective effects of **modafinil** in MPTP-treated common marmoset)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:200477 HCAPLUS
DN 131:39566
TI The vigilance-promoting drug **modafinil** increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade
AU Ferraro, Luca; Antonelli, Tiziana; Tanganelli, Sergio; O'Connor, William T.; De la Mora, Miguel Perez; Mendez-Franco, Jesus; Rambert, Francis A.; Fuxe, Kjell
CS Department of Clinical and Experimental Medicine, Pharmacology Section, University of Ferrara, Ferrara, Italy

SO Neuropsychopharmacology (1999), 20(4), 346-356
CODEN: NEROEW; ISSN: 0893-133X
PB Elsevier Science Inc.
DT Journal
LA English
AB The effects of **modafinil** on glutamatergic and GABAergic transmission in the rat medial preoptic area (MPA) and posterior hypothalamus (PH) were analyzed. **Modafinil** (30-300 mg/kg) increased glutamate and decreased GABA concns. in the MPA and PH. Local perfusion with the GABAA agonist muscimol (10 .mu.M) reduced, while the GABAA antagonist bicuculline (1 .mu.M and 10 .mu.M) increased, glutamate. The **modafinil** (100 mg/kg)-induced increase of glutamate was antagonized by local perfusion with bicuculline (1 .mu.M). When glutamate concns. were increased by local perfusion with the glutamate uptake inhibitor L-trans-PDC (0.5 mM), **modafinil** produced an addnl. enhancement of glutamate concns. **Modafinil** (1-33 .mu.M) failed to affect [3H]glutamate uptake in hypothalamic synaptosomes and slices. These findings show that **modafinil** increases glutamate and decreases GABA in the MPA and PH. The evidence that bicuculline counteracts the **modafinil**-induced increase of glutamate strengthens the evidence for an inhibitory GABA/glutamate interaction in the above regions, which control the sleep-wakefulness cycle.
IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**modafinil** effects on extracellular glutamate and GABA in the medial preoptic area and the posterior hypothalamus)
RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:439446 HCAPLUS
DN 125:104992
TI The vigilance promoting drug **modafinil** increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism
AU Ferraro, Luca; Tanganelli, Sergio; O'Connor, William Thomas; Antonelli, Tiziana; Rambert, Francis; Fuxe, Kjell
CS Institute of Pharmacology, University of Ferrara, Ferrara, Italy
SO European Journal of Pharmacology (1996), 306(1-3), 33-39
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English
AB The present in vivo microdialysis study demonstrated that the s.c. injection of **modafinil** (diphenyl-methyl-sulfinyl-2-acetamide) in doses of 30-300 mg/kg dose dependently increased dopamine release from the intermediate level of the nucleus accumbens along the rostro-caudal axis of the halothane anesthetized rat. The effect of **modafinil** in a dose of 100 mg/kg was counteracted by the local perfusion in the nucleus accumbens with the GABAB receptor antagonist phaclofen (.beta.-p-chlorophenyl-.gamma.-aminopropyl-phosphonic acid) (50 .mu.M), the GABAA agonist muscimol (3-hydroxy-5-aminomethyl-isoxazolol) (10 .mu.M) and the neuronal GABA reuptake inhibit SKF89976A (4,4-diphenyl-3-butenyl-

nipecotic acid) (0.1 .mu.M), where it was increased by the GABAB receptor agonist (-)-baclofen [.beta.-(p-chlorophenyl-.gamma.-aminobutyric acid)] (1- .mu.M). In addn., the **modafinil**-induced increase of dopamine release was assocd. with a significant redn. of accumbens GABA release. These results suggest that the dopamine releasing action of **modafinil** in the rat nucleus accumbens is secondary to its ability to reduce local GABAergic transmission, which leads to a redn. of GABAA receptor signaling on the dopamine terminals.

IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(the vigilance promoting drug **modafinil** increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism)

RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1992:248290 HCAPLUS
DN 116:248290
TI Inhibitory effects of the psychoactive drug **modafinil** on .gamma.-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig. Possible involvement of 5-hydroxytryptamine mechanisms
AU Tanganelli, S.; Fuxe, K.; Ferraro, L.; Janson, A. M.; Bianchi, C.
CS Dep. Pharmacol., Univ. Ferrara, Ferrara, Italy
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1992), 345(4), 461-5
CODEN: NSAPCC; ISSN: 0028-1298
DT Journal
LA English
AB The effects of **modafinil** on acetylcholine and GABA outflow from the cerebral cortex of awake freely moving guinea pigs provided with an epidural cup were studied. In the dose range of 3-30 mg/kg s.c., **modafinil** produced a dose dependent significant inhibition of GABA outflow without influencing cortical acetylcholine release. Methysergide (2 mg/kg, i.p.) and ketanserin (0.5 mg/kg, i.p.) but not prazosin (0.14 mg/kg, i.p.) counteracted the inhibitory action of **modafinil** on cortical GABA outflow. **Modafinil** both acutely and chronically in the same dose range increased striatal 5-HIAA levels and 5-HT utilization in the rat (acute) and mouse (chronic). The action on cortical GABA release may be dependent on activity at 5-HT2 receptors, since the action of **modafinil** in this respect is blocked by the non-selective 5-HT antagonist methysergide and the 5-HT2 antagonist ketanserin. The involvement of 5-HT mechanisms in the inhibitory action of **modafinil** on cortical GABA release is also suggested by the findings that 5-HT metab. may become increased by **modafinil** at least in the striatum. The redn. of cortical GABA outflow via 5-HT2 receptors by **modafinil** is probably related to some of its actions on the central nervous system including behavioral effects.

IT **68693-11-8, Modafinil**
RL: BIOL (Biological study)
(acetylcholine and GABA release response to, in brain cortex, serotoninergic S2 receptor mediation of)

RN 68693-11-8 HCAPLUS
CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



=> fil mrck
FILE 'MRCK' ENTERED AT 06:22:43 ON 10 OCT 2002

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: APRIL 2001

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all

L30 ANSWER 1 OF 1 MRCK
MERCK Number (MNO): 6311
CAS Registry No. (RN): **68693-11-8**
MERCK Index Name (MIN): **Modafinil**
CA Index Name (CN): 2-[(Diphenylmethyl)sulfinyl]acetamide
Synonym(s) (CN): 2-(benzhydrylsulfinyl)acetamide
Drug Code(s) (CN): **CRL-40476**
Trade Name(s) (CN): **Provigil (Cephalon)**
Molecular Form. (MF): C15 H15 N O2 S
Wgt Composition (COMP): C 65.91%, H 5.53%, N 5.12%, O 11.71%, S 11.73%.
Molecular Weight (MW): 273.36
References (RE): .alpha.1-Adrenergic agonist. Prepn: L. Lafon, Ger. pat. 2809625; eidem, U.S. pat. 4177290 (1978, 1979 both to Lab. Lafon). Effects on vigilance: F. Goldenberg, J. S. Weil, Sleep (Stuttgart) 8, 343 (1988); on normal sleep: B. Saletu et al., Int. J. Clin. Pharmacol. Res. 9, 183 (1989). Clinical evaluation in hypersomnia and narcolepsy: H. Bastuji, M. Jouvet, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 12, 695 (1988).



Melting Point (MP):

Value MP deg C
164 - 166

Other Properties (OCPP):
Crystals from methanol, mp 164-166.degree. .

Therapeutic Codes (THER):
CNS Stimulant.
Referenced Patent (RPN):
DE2809625; US4177290

```
=> d his

     (FILE 'HOME' ENTERED AT 13:42:03 ON 09 OCT 2002)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 13:42:25 ON 09 OCT 2002
               E MODAFINIL/CN
L1             1 S E3
L2             1 S E4
L3           431 S C15H15NO2S/MF AND 46.150.18/RID AND 2/NR
L4            37 S L3 AND ACETAMIDE
L5             4 S L4 AND DIPHENYLMETHYL
L6             3 S L5 NOT HYDROXY
L7             3 S L1,L6 AND MODAFINIL
L8           333 S C15H14O3S/MF AND 46.150.18/RID AND 2/NR
L9             3 S L8 AND ACETIC ACID AND DIPHENYLMETHYL
L10            3 S L2,L9
               SEL RN L7
L11            5 S E1-E3/CRN
               SEL RN L10
L12            2 S E4-E6/CRN

     FILE 'HCAOLD' ENTERED AT 14:16:11 ON 09 OCT 2002
L13            0 S L7
L14            0 S L11

     FILE 'HCAPLUS' ENTERED AT 14:16:11 ON 09 OCT 2002
L15            1 S L11
L16          143 S L7
L17          157 S MODAFINIL OR PROVIGIL OR MODIODAL OR CRL40476 OR CRL()(40476
L18          160 S L16,L17
L19            3 S L18 AND ?CYCLODEXTRIN?

     FILE 'REGISTRY' ENTERED AT 14:21:31 ON 09 OCT 2002
L20            6 S 12619-70-4 OR 10016-20-3 OR 7585-39-9 OR 17465-86-0 OR 85220-
L21        22279 S (13750 OR 14099 OR 14246 OR 30188 OR 57602)/RID
L22        23429 S ?CYCLODEXTRIN?/CNS
L23        23725 S L21,L22 NOT L20

     FILE 'HCAPLUS' ENTERED AT 14:24:01 ON 09 OCT 2002
L24        14041 S L20
L25        10005 S L23
L26            2 S L18 AND L24,L25
L27            3 S L15,L19,L26
L28            2 S L27 NOT CHROMATOGRAPHY/TI
               E JACOBS M/AU
L29          170 S E3,E15-E18
               E JACOBS MARTIN/AU
L30           19 S E3,E8,E9
               E MARTIN J/AU
L31         4190 S E3-E82,E94-E96
               E PIYUSH P/AU
L32            1 S E2
               E PATEL P/AU
L33          812 S E3-E24
               E PATEL PIYUSH/AU
L34           33 S E3-E8
L35            3 S L18 AND L29-L34
               E CEPHALON/PA,CS
L36          270 S E3-E23
L37           21 S L18 AND L36
L38            2 S L35,L37 AND (L24,L25 OR ?CYCLODEXTRIN?)
L39            5 S L26-L28,L35,L38
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
L40           1 S L39 AND L11
L41           5 S L39,L40
                E DRUG BIOAVAILABILITY/CT
                E E3+ALL
L42       13090 S E3
                E E6+ALL
L43        3389 S E5,E4+NT
                E E9+ALL
L44        6372 S E2+NT
                E PHARMACOKINETICS/CT
                E E3+ALL
L45       12487 S E2+NT
                E E11+ALL
L46       57131 S E3+NT
L47          12 S L18 AND L42-L46
                SEL DN AN 8
L48           1 S L47 AND E1-E3
L49          97 S L7 (L) (ADV OR BCP OR BPR OR BSU OR DMA OR MFM OR PAC OR PKT)
L50          97 S L49 AND L18
L51           2 S L41,L48 AND L50
L52           6 S L41,L48,L51
L53          85 S L50 NOT L52,L47
                SEL DN AN 31 38 50 52 55 58 62 63 71 72
L54          10 S L53 AND E4-E33
L55          16 S L52,L54
L56          59 S L18 NOT L47-L55
                SEL DN AN 22 25
L57           2 S L56 AND E34-E39
L58          18 S L55,L57 AND L15-L19,L24-L57
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:04:31 ON 09 OCT 2002
L59          14 S E40-E53
L60           8 S L59 AND L7,L11
L61           6 S L59 AND L20,L23 NOT L60

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:06:09 ON 09 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 OCT 2002  HIGHEST RN 459783-15-4
DICTIONARY FILE UPDATES:   7 OCT 2002  HIGHEST RN 459783-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l60

L60  ANSWER 1 OF 8  REGISTRY  COPYRIGHT 2002 ACS
```

RN **443128-12-9** REGISTRY
CN .beta.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H70 O35 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **443128-11-8** REGISTRY
CN .beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6A,6B,6C,6D,6E,6F,6G-heneicosa-O-methyl-, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C63 H112 O35 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 55216-11-0
CMF C63 H112 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **443128-10-7** REGISTRY
CN .beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,6A,6B,6C,6D,6E,6F,6G-tetradeca-O-methyl-, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI) (CA INDEX NAME)
MF C56 H98 O35 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 51166-71-3
CMF C56 H98 O35



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **443128-09-4** REGISTRY
CN .gamma.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI) (CA INDEX NAME)
MF C48 H80 O40 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 17465-86-0
CMF C48 H80 O40





1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **443128-08-3** REGISTRY
CN .alpha.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H60 O30 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 10016-20-3
CMF C36 H60 O30

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **112111-47-4** REGISTRY
CN **Acetamide, 2-[(diphenylmethyl)sulfinyl]-, (+)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(+)-Modafinil**
CN CRL 40983
FS STEREOSEARCH
MF **C15 H15 N O2 S**
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:47896

REFERENCE 2: 131:237446

REFERENCE 3: 131:164943

REFERENCE 4: 117:137769

REFERENCE 5: 112:35457

L60 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **112111-43-0** REGISTRY
CN **Acetamide, 2-[(diphenylmethyl)sulfinyl]-, (-)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(-)-Modafinil**
CN CRL 40982
FS STEREOSEARCH
MF **C15 H15 N O2 S**
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:47896

REFERENCE 2: 131:237446

REFERENCE 3: 131:164943

REFERENCE 4: 117:137769

REFERENCE 5: 112:35457

L60 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **68693-11-8** REGISTRY
CN **Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(.+-.)-Modafinil**
CN **2-(Benzhydrylsulfinyl)acetamide**
CN CEP 1538
CN CRL 40476
CN **Modafinil**
CN Modiodal
CN Provigil
FS 3D CONCORD
DR 112111-49-6
MF **C15 H15 N O2 S**
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

140 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
140 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:210420

REFERENCE 2: 137:179735

REFERENCE 3: 137:134949

REFERENCE 4: 137:114532

REFERENCE 5: 137:109489

REFERENCE 6: 137:98838

REFERENCE 7: 137:88283

REFERENCE 8: 137:57438

REFERENCE 9: 137:41638

REFERENCE 10: 137:41220

=> d ide can tot l61

L61 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **55216-11-0** REGISTRY
CN **.beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6A,6B, 6C,6D,6E,6F,6G-heneicosa-O-methyl- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradecaoxaoctacyclo[31.2.2.23 ,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin deriv.**
OTHER NAMES:
CN **.beta.-Cyclodextrin permethyl ether**
CN **2,3,6-Tri-O-methyl-.beta.-cyclodextrin**
CN **2,3,6-Trimethyl-.beta.-cyclodextrin**
CN Cydex-.beta.
CN **Heptakis(2,3,6-tri-O-methyl)-.beta.-cyclodextrin**
CN **Heptakis(2,3,6-trimethyl)-.beta.-cyclodextrin**
CN Hydrodex .beta.-PM
CN **Permethyl-.beta.-cyclodextrin**
CN **Permethylated .beta.-cyclodextrin**
CN **Tri-O-methyl-.beta.-cyclodextrin**
CN TRIMEB
CN **Trimethyl-.beta.-cyclodextrin**
FS STEREOSEARCH
DR 74948-17-7
MF C63 H112 O35
CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, PIRA, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

550 REFERENCES IN FILE CA (1962 TO DATE)
27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
551 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:185208

REFERENCE 2: 137:184497

REFERENCE 3: 137:179088

REFERENCE 4: 137:114532

REFERENCE 5: 137:83754

REFERENCE 6: 137:83751

REFERENCE 7: 137:68183

REFERENCE 8: 137:68177

REFERENCE 9: 137:37662

REFERENCE 10: 137:33465

L61 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **51166-71-3** REGISTRY
CN **.beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,6A,6B,6C,6D,6E,6F,6G-tetradeca-O-methyl- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin deriv.**
OTHER NAMES:
CN **2,6-Di-O-methyl-.beta.-cyclodextrin**
CN **2,6-Dimethyl-.beta.-cyclodextrin**
CN **2A,6A-Di-O-methyl-.beta.-cyclodextrin**
CN Beta W7 M 1.8
CN **Di-O-methyl-.beta.-cyclodextrin**
CN Dimeb
CN **Dimethyl-.beta.-cyclodextrin**
CN **Heptakis(2,6-di-O-methyl)-.beta.-cyclodextrin**
CN **Heptakis(2,6-di-O-methyl)-.beta.-cyclodextrin**
CN **Tetradeca-O-methyl-.beta.-cyclodextrin**
CN Tetradecakis-2,6-O-methylcycloheptaamylose
DR 120837-54-9, 97568-70-2, 99237-56-6, 95176-10-6, 103346-40-3, 106236-73-1, 84346-59-8, 107031-56-1
MF C56 H98 O35
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CSCHEM, DETHERM*, EMBASE, GMELIN*, IPA, MEDLINE, MSDS-OHS, PHAR, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



1016 REFERENCES IN FILE CA (1962 TO DATE)
65 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1016 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:185208

REFERENCE 2: 137:184497

REFERENCE 3: 137:174673

REFERENCE 4: 137:129668

REFERENCE 5: 137:114532

REFERENCE 6: 137:109576

REFERENCE 7: 137:90458

REFERENCE 8: 137:83644

REFERENCE 9: 137:68183

REFERENCE 10: 137:68177

L61 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **17465-86-0** REGISTRY
CN .gamma.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-Hexadecaoxanonacyclo[36.2.2.23
,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontane,
.gamma.-cyclodextrin deriv.
OTHER NAMES:
CN .gamma.-Dextrin
CN Cyclomaltooctaose
CN Cyclooctaamylose
CN Dexy Pearl .gamma.-100
CN Ringdex C

CN Stereoisomer of 5,10,15,20,25,30,35,40-octakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-hexadecaoxanonacyclo[36.2.2.23,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontane-41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56-hexadecol

DR 216309-81-8, 217487-02-0

MF C48 H80 O40

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, PHAR, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2945 REFERENCES IN FILE CA (1962 TO DATE)
657 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2956 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:223998

REFERENCE 2: 137:222192

REFERENCE 3: 137:222086

REFERENCE 4: 137:222063

REFERENCE 5: 137:222056

REFERENCE 6: 137:218653

REFERENCE 7: 137:218647

REFERENCE 8: 137:211064

REFERENCE 9: 137:210090

REFERENCE 10: 137:195237

L61 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **12619-70-4** REGISTRY
CN Cyclodextrin (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Celdex
CN Celdex CH 20
CN Celdex CH 30
CN Celdex SH 20
CN Celdex SH 40
CN Celdex TB 50
CN Cycloamylose
CN Cyclodextrins
CN Rhodocap L 20
CN Ringdex P
DR 100091-36-9
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
3462 REFERENCES IN FILE CA (1962 TO DATE)
1076 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3469 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:222054

REFERENCE 2: 137:216133

REFERENCE 3: 137:212301

REFERENCE 4: 137:212297

REFERENCE 5: 137:210054

REFERENCE 6: 137:206536

REFERENCE 7: 137:200358

REFERENCE 8: 137:194679

REFERENCE 9: 137:190770

REFERENCE 10: 137:184455

L61 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **10016-20-3** REGISTRY
CN .alpha.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4,7,9,12,14,17,19,22,24,27,29-Dodecaoxaheptacyclo[26.2.2.23,6.28,11.213, 16.218,21.223,26]dotetracontane, .alpha.-cyclodextrin deriv.
CN Cyclohexaamylose (6CI)
OTHER NAMES:
CN .alpha.-Cycloamylose

CN .alpha.-Dextrin
CN .alpha.-Schardinger dextrin
CN Alfadex
CN Celdex A 100
CN Cyclohexadextrin
CN Cyclomaltohexaose
CN Cyclomaltohexose
CN Dextrin, .alpha.-cyclo
CN Dexy Pearl .alpha.-100
CN Ringdex A
CN Stereoisomer of 5,10,15,20,25,30-hexakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29-dodecaoxaheptacyclo[26.2.2.23,6.28,11.213,16.218,21.223,26]dotetracontane-31,32,33,34,35,36,37,38,39,40,41,42-dodecol
FS STEREOSEARCH
DR 23513-50-0, 41871-62-9, 47910-04-3
MF C36 H60 O30
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3820 REFERENCES IN FILE CA (1962 TO DATE)
762 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3835 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:223998

REFERENCE 2: 137:222192

REFERENCE 3: 137:222063

REFERENCE 4: 137:222056

REFERENCE 5: 137:218653

REFERENCE 6: 137:217146

REFERENCE 7: 137:211064

REFERENCE 8: 137:210090

REFERENCE 9: 137:201551

REFERENCE 10: 137:197713

L61 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2002 ACS
RN **7585-39-9** REGISTRY
CN .beta.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin deriv.
CN Cycloheptaamylose (7CI)
OTHER NAMES:
CN .beta.-Cycloamylose
CN .beta.-Cycloheptaamylose
CN .beta.-Dextrin
CN Betadex
CN Cavamax W 7
CN Celdex B 100
CN Celdex N
CN Cycloheptaglucan
CN Cycloheptaglucosan
CN Cyclomaltoheptaose
CN Dextrin, .beta.-cyclo
CN Kleptose
CN Kleptose B
CN NSC 314334
CN Rhodocap N
CN Ringdex B
CN Ringdex BL
CN Schardinger .beta.-dextrin
CN Stereoisomer of 5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
FS STEREOSEARCH
DR 449728-55-6, 37331-89-8, 47918-72-9
MF C42 H70 O35
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9909 REFERENCES IN FILE CA (1962 TO DATE)
3657 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10004 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:225951

REFERENCE 2: 137:223998

REFERENCE 3: 137:223323

REFERENCE 4: 137:222192

REFERENCE 5: 137:222187

REFERENCE 6: 137:222185

REFERENCE 7: 137:222063

REFERENCE 8: 137:222056

REFERENCE 9: 137:221916